WVU Cancer Institute

Although the 5-year survival rate has improved to about 13 percent, pancreatic cancer remains one of the deadliest cancers, often diagnosed at advanced stages with limited treatment options.

A large transcriptomic analysis identified actionable gene fusions in 9% of glioblastomas, defining a targetable molecular subset.

A WVU Cancer Institute team investigated the efficacy of subcutaneous blinatumomab in treating one of the rarest and most aggressive forms of leukemia.

Patients with pancreatic lesions have been treated with endoscopy-guided microwave therapy according to researchers at WVU Medicine.

The expansion of WVU Medicine hospitals across the state is changing how and where patients, including those with cancer, receive care.